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Abstract
Novel developments in genomic medicine may reduce the length of the diagnostic odyssey for patients with rare diseases. 
Health providers must thus decide whether to offer genome sequencing for the diagnosis of rare conditions in a routine clini-
cal setting. We estimated the costs of singleton standard genetic testing and trio-based whole genome sequencing (WGS), in 
the context of the Scottish Genomes Partnership (SGP) study. We also explored what users value about genomic sequenc-
ing. Insights from the costing and value assessments will inform a subsequent economic evaluation of genomic medicine in 
Scotland. An average cost of £1,841 per singleton was estimated for the standard genetic testing pathway, with significant 
variability between phenotypes. WGS cost £6625 per family trio, but this estimate reflects the use of WGS during the SGP 
project and large cost savings may be realised if sequencing was scaled up. Patients and families valued (i) the chance of 
receiving a diagnosis (and the peace of mind and closure that brings); (ii) the information provided by WGS (including impli-
cations for family planning and secondary findings); and (iii) contributions to future research. Our costings will be updated 
to address limitations of the current study for incorporation in budget impact modelling and cost-effectiveness analysis (cost 
per diagnostic yield). Our insights into the benefits of WGS will guide the development of a discrete choice experiment 
valuation study. This will inform a user-perspective cost–benefit analysis of genome-wide sequencing, accounting for the 
broader non-health outcomes. Taken together, our research will inform the long-term strategic development of NHS Scotland 
clinical genetics testing services, and will be of benefit to others seeking to undertake similar evaluations in different contexts.
Keywords Whole genome sequencing · Diagnostic odyssey · Costs and benefits · Economic evaluation · Valuation
Introduction
Rare conditions collectively affect approximately 8% of the 
Scottish population (Scottish Government 2014). Many are 
severe and life threatening, with a profound impact upon 
the quality of life and wellbeing of the individual and their 
family. The typical journey to diagnosis involves a complex 
pathway of clinical and genetic tests, hospital appointments 
and considerable uncertainty for patients and families. This 
‘diagnostic odyssey’ can take many years. Whilst Scottish 
patients wait an average of 4 years before receiving a diag-
nosis for their rare condition, many never receive a diagnosis 
(Scottish Government 2014). The diagnostic odyssey has 
a detrimental impact on health-related quality of life and 
well-being (Hilbert et al. 2013). Given around that 80% of 
rare conditions have a genetic origin, increasing access to 
genetic testing is a key component of global health policy 
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decisions that aim to improve the lives of people with rare 
diseases and their families (Stark et al. 2019).
Novel developments in genomic medicine, such as whole 
genome sequencing (WGS) and whole exome sequencing 
(WES), may offer an opportunity to shorten the diagnostic 
odyssey for patients and families who live with unexplained 
rare conditions. The comprehensive sequence analysis of a 
person’s entire genome may increase the proportion of cases 
receiving a positive molecular diagnosis, enabling quicker 
diagnosis for rare diseases (Ontario Health 2020). In the 
UK, initiatives such as the 100,000 Genomes Project have 
delivered WGS using gene panel analysis to patients in a 
research context. Following their involvement in the 100,000 
Genomes Project through the Scottish Genomes Partnership 
(SGP) (Scottish Genomes Partnership 2020), the Scottish 
Government announced a £4.2 million bridge funding pack-
age for NHS Scotland’s genetics services, in part to support 
ongoing evaluation of WGS and to inform future service 
delivery. This interim funding aims to support the continued 
momentum of genomics for the diagnosis of rare conditions 
in Scotland, acting as a bridge until there is sufficient evi-
dence to inform a Scottish genomic testing strategy (NHS 
Scotland 2019).
Whilst there is a growing literature on the costs (Schwarze 
et al. 2018; Plöthner et al. 2017; Van Nimwegen et al. 2016; 
Tsiplova et al. 2017) and benefits (Chassagne et al. 2019; 
Marshall et al. 2016; Peyron et al. 2018; Regier et al. 2015) 
of WGS, to date, no studies have addressed this issue in a 
Scottish context. In research conducted alongside the Scot-
tish bridge funding, and funded by the SGP and Chief Sci-
entist Office of the Scottish Government, we are conducting 
an economic evaluation of WGS in Scotland (Chief Scientist 
Office 2019). Whilst the cost per QALY framework (Wey-
mann et al. 2019; Lejeune and Amado 2021; Buchanan et al. 
2021) is employed within Scotland to make recommenda-
tions for drugs (Scottish Medicines Consortium 2017) and 
technologies (Scottish Health Technologies Group 2017), 
decisions regarding the provision of genomic services cur-
rently lie with the National Services Division (NSD) of NHS 
Scotland. ‘Value for money’ decisions are often being made 
on the basis of cost-effectiveness, with a focus on outcomes 
such as diagnostic yield, adverse events and hospital attend-
ances, as well as budget impact considerations (National 
Services Scotland 2019, 2019). However, the recent report 
of the Scottish Scientific Advisory Council (SSAC) on the 
future of genomic medicine (SSAC 2019) identified the 
need to use both ‘standard and value-based health economic 
models to compare efficiency, cost-effectiveness and patient 
perspectives’.
This paper reports on research we have conducted to 
inform an economic evaluation of WGS in Scotland. At 
this time, we are not considering these findings with respect 
to diagnostic yield or in comparison with exome tests, nor 
undertaking formal cost-effectiveness or cost–benefit analy-
sis. Instead, we seek to identify aspects of study design that 
must be considered to effectively evaluate genome-scale test-
ing for clinical diagnosis. The rest of the paper is organised 
as follows. We first provide information on the context of 
our study, the Scottish Genomes Partnership (SGP). This is 
followed by the methods used to estimate the cost of single-
ton standard genetic testing and trio-based whole genome 
sequencing. We then present the qualitative methods used in 
an interview study designed to identify the benefits of whole 
genome sequencing. We then present our findings for each of 
component of the study, and draw our findings together in a 
discussion, highlighting future areas for research to ensure 
we can accurately assess and compare the costs and benefits 
of standard care and genomic sequencing for the diagnosis 
of rare disorders in Scotland.
Study context: the Scottish Genomes 
Partnership
Our study participants are probands and parents from the 
SGP study, ‘Scottish Participation in the 100,000 Genomes 
Project’ (Scottish Genomes Partnership 2020). SGP is a 
pan-Scotland initiative designed to explore applications 
of genomics to solve clinical problems through academic, 
NHS clinical and industrial collaborations. Alignment of 
the SGP with the 100,000 Genomes Project is a policy aim 
of the Scottish Government (SG), supported through direct 
funding of associated research by the SG’s Chief Scientist 
Office (CSO) and the Medical Research Council (MRC). 
For research with NHS rare disease cohorts, the SGP devel-
oped a research collaboration with Genomics England for 
participation in the 100,000 Genomes Project to investigate 
the extent to which WGS with collaborative analysis could 
improve genetic testing and clinical follow-up for rare dis-
ease patients. ‘Collaborative analysis’ refers to the collabo-
ration between the SGP and Genomics England, between 
Scotland’s four regional genetics centres, as well as between 
clinicians, scientists and universities. The SGP study oper-
ated under a distinct research protocol to the rest of the UK 
with some key differences. Of relevance here, Scottish sam-
ples were not sent to Genomics England for sequencing, but 
instead sequenced in Scotland with data then shared with 
Genomics England.
Eligibility criteria for the SGP study are shown in Online 
Resource 1. Briefly, probands and first-degree relatives 
were recruited via NHS Scotland’s regional genetics ser-
vices. DNA samples were extracted by the regional genet-
ics laboratories and sent to the University of Edinburgh for 
sequencing using a HiSeqX. De-identified clinical data and 
encrypted FASTQ data files were transferred to Genomics 
England for generation of Variant Call and BAM files plus 
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bioinformatics analysis, trio-based analysis and storage. 
Results were shared with the regional genetics laboratories 
for interpretation, validation and clinical reporting through a 
browser. At the time of this study, interpretation and report-
ing were ongoing; however, most patients/families have now 
received a study report.
Methods
Costing the standard genetic testing pathway
There is uncertainty around the nature and cost of both the 
standard genetic testing pathway and WGS for the diagnosis 
of rare conditions. Costing studies vary in both their defi-
nition of the standard testing pathway and components of 
cost included when evaluating WGS, making comparisons 
difficult (Schwarze et al. 2018; Yuen et al. 2018; Plöthner 
et al. 2017; Tsiplova et al. 2017; Payne et al. 2018; Ontario 
Health 2020). Furthermore, whilst the cost of trio-based 
WGS for the diagnosis of rare conditions has been estimated 
in an English context (Schwarze et al. 2018), no study has 
estimated the costs of standard genetic testing or trio-based 
WGS in Scotland specifically. We aim to fill this gap.
We define the standard genetic testing pathway as the 
second-line genetic testing component of the diagnostic 
odyssey undertaken after any initial chromosomal microar-
ray, FISH and/or karyotype for singleton probands. Although 
a full diagnostic odyssey for rare diseases typically involves 
a wider range of clinical, biochemical and metabolic tests, 
followed by chromosomal microarray, FISH and/or karyo-
type, we assume that WGS would replace the genetic testing 
‘sub-odyssey’ including single gene testing, multiple gene 
panel testing and epigenetic testing.
An exemplar diagnostic odyssey for a singleton rare dis-
ease patient with a neurodevelopmental disorder, and the 
standard genetic testing pathway, or sub-odyssey, is pre-
sented in Fig. 1. The initial stage at which a rare disease 
patient presents to the health service depends on factors such 
as age and phenotype: adult-onset conditions may be more 
likely to be referred from primary care whilst conditions 
present from birth may be more likely to proceed imme-
diately to specialist care. Additionally, the ending point of 
a diagnostic odyssey depends on the condition and what 
tests are available and can change over time as new tests 
are discovered.
The cost of the genetic testing sub-odyssey was estimated 
for each patient and each rare disease category. These cat-
egories were defined according to the Genomics England 
classification for rare diseases (Genomics England 2018) 
We extracted data on relevant prior testing histories from 
the SGP study participants’ WGS eligibility screening 
forms (see Online Resource 1), completed when patients 
were referred to Scotland’s four regional genetics centres. 
Eligibility screening forms were available for 393 probands. 
However, 134 probands were not costed due to missing 
information and/or unidentifiable genetic test names on 
eligibility screening forms (especially where handwritten). 
Data on testing histories for the remaining 259 probands 
did not include the date of the test, and therefore, it was 
not possible to estimate annualised costs for a proband’s 
standard testing pathway. All costs were estimated from an 
NHS Scotland perspective and reported in British Pounds 
(£) at 2018 prices.
For tests performed in Scotland, we attached unit costs 
provided by NHS Scotland’s genetics laboratories (reflect-
ing likely costs to NHS Scotland). For tests conducted in 
laboratories in other parts of the UK, unit costs were sourced 
from these laboratories. This included several NHS England 
genetics laboratories. Additional information was sourced 
from the UK Genetics Testing Network. For tests where a 
unit cost was not available, costs were based on the number 
of amplicons or exons in the gene, following the GenU sys-
tem for estimating resource use in laboratories for genetic 
tests (Norbury et al. 2016). Test costs increase with higher 
numbers of amplicons or exons as this reflects the number of 
days to report and therefore laboratory workload. An aver-
age cost per test was calculated for each of five ranges of 
number of amplicons or exons (1–10, 11–20, 21–30, 31–40 
and 41 +). Further details of the sources for unit costs are 
shown in Online Resource 2.
To estimate the cost of associated hospital attendances 
(general outpatient and genetics clinic visits), unit costs were 
taken from NHS Reference costs (Reference Cost Collection, 
2017–18). Due to unavailability of data on hospital attend-
ances, our clinical advisors suggested an average of two out-
patient appointments and one genetic outpatient appointment 
per patient.
Costing trio‑based whole genome sequencing
The WGS testing pathway reflects trio-based testing as per 
the SGP study protocol. A summary of the WGS pathway 
is illustrated in Fig. 2. Case eligibility discussion involved 
three or more consultant geneticists, typically covering five 
to seven cases in around one to 2 h, including preparation 
time. Consent was obtained by a genetics counsellor and 
phenotype data for all affected family members was entered 
into a database. Following review of stored DNA in the local 
diagnostic molecular genetic laboratory, 40% of probands 
did not require a new DNA sample. Entering phenotype data 
for all affected family members into the database was esti-
mated to take between 15 min and 1 h. The regional genet-
ics laboratory performed quality control checks before an 
aliquot of DNA was transferred into a 2D barcoded tube and 
sent to a central sequencing centre (Edinburgh Genomics) 
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where sequencing was based on a service agreement for 
Human 30 × or 120 GB yield WGS, with PCR free libraries 
on the HiSeq X, returning FASTQ, BAM and VCF files. 
Coverage was calculated from good quality reads after 
removing overlapping bases and duplicated reads, after 
adaptor trimming, quality trimming and semi-aligned read 
clipping, and using well-mapped reads (mapQ > 10). Each 
FASTQ file contained at least 80 ×  109 bases with at least 
95% genome covered at 15x or above.
An encrypted FASTQ data file created by the sequenc-
ing centre was then sent to GeL for data analysis after 
which a report is returned to NHS Scotland clinical sci-
entists. Long-term (indefinite) data storage is provided 
by GeL. Each regional genetics laboratory received the 
analysis report for interpretation and validation, to confirm 
variants of clinical significance. Initially, results were 
interpreted by a clinical scientist in line with the Ameri-
can College of Medical Genetics (ACMG) guidelines 
(Richards et al. 2015) for determining pathogenicity, then 
discussed at a multi-disciplinary team (MDT) meeting. 
Where considered likely to be causative, findings were 
confirmed by Sanger sequencing. Our estimated cost per 
sample and per trio, sourced from the NHS Grampian 
laboratory, is based on Sanger sequencing on the original 
DNA sample and an assumed annual throughput of 100 
samples (equivalent to 33 family trios).
Following laboratory validation, a report was issued to 
the original referring clinician and information relevant to 
the participant’s primary condition was fed back to families.
Fig. 1  A typical diagnostic 
odyssey for a rare disease 
patient with a neurodevelop-
mental condition. This figure 
illustrates a typical ‘diagnostic 
odyssey’ for a rare disease 
patient with a neurodevelop-
mental condition. The iterative 
genetic testing ‘sub-odyssey’ is 
indicated by the black arrows. 
This portion of the overall 
diagnostic odyssey was costed 
in this paper, as it was deemed 
most likely to be replaced by 
WGS
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1 3
At the time of the study, WGS was not routinely practised 
in NHS Scotland and the process for reviewing results was 
not fully developed. We based our MDT meeting costs on 
the experience in the NHS Grampian genetics clinic during 
the SGP Project: It was assumed that 50% of WGS reports 
require discussion at an MDT meeting (based on the case 
mix seen in the NHS Grampian genetics clinic at that time) 
and that all probands attended follow-up.
Micro-costing, a technique, where detailed inputs of staff 
time, consumables and equipment requirements are esti-
mated, was used to determine the resources used at NHS 
Scotland regional genetics laboratories and clinics (Raft-
ery 2000). Staff time was estimated at salary grade mid-
point with an allowance for clinic and laboratory overheads. 
Equipment costs are based on the annual equivalent costs for 
capital, plus allocated maintenance costs in 2018, adjusted 
using RPI inflation where required and discounted using 
3.5% discount rate (Drummond et al. 2015) over specific 
lifetime of equipment. To calculate the capital cost per trio, 
the proportion of capital equipment time used for WGS 
was estimated based on diagnostic laboratory opinion. This 
was estimated to be < 1% for most capital charges, based 
Fig. 2  Figure 2 illustrates the 
whole genome sequencing path-
way, as delivered in the Scottish 
Genomes Partnership’s involve-
ment in the 100,000 Genomes 
Project. The parts of the WGS 
pathway which were micro-
costed are indicated by the blue 
brackets, while the parts which 
were costed based on charges to 
the regional genetics centres are 
indicated by the red bracket
 Journal of Community Genetics
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on assumed annual throughput for laboratory processing of 
WGS samples.
For resource use outside of NHS Scotland regional genet-
ics clinics and laboratories, micro-costing was not possible 
due to commercial confidentiality. Costings were thus based 
on charges to regional genetics centres, based on service 
agreements during the SGP study. This charge-based costing 
included sample sequencing by a central sequencing centre 
(Edinburgh Genomics) and data processing and storage by 
GeL.
As with standard genetic testing, all costs are estimated 
from an NHS Scotland perspective and reported in British 
Pounds (£) at 2018 prices.
Identifying the benefits of whole genome 
sequencing in Scotland
Health economic evaluations of WGS and standard genetic 
testing have tended to define benefits in terms of diagnostic 
yield (the proportion of cases receiving a genetic diagnosis) 
(Weymann et al. 2019; Phillips et al. 2018; Schwarze et al. 
2018; Smith et al. 2019; Zhang et al. 2019). More recently, 
however, there has been recognition of the relevance and 
importance of non-health outcomes and process factors to 
service users. This has led to a small but growing litera-
ture applying preference-based valuation methods, namely 
discrete choice experiments (DCEs) and willingness to pay 
(WTP) studies (Bennette et al. 2013; Buchanan et al. 2016; 
Chassagne et al. 2019; Goranitis et al. 2020; Lewis et al. 
2018; Marshall et al. 2016; Peyron et al. 2018; Regier et al. 
2015; Regier et al. 2018; Marshall et al. 2019; Weymann 
et al. 2018). This literature suggests that important factors 
extend beyond diagnostic yield, and include aspects such as 
waiting time for results, information provided and chance 
of improving health care provided and available treatments. 
However, no study has investigated the benefits of standard 
genetic testing or trio-based WGS to service users in NHS 
Scotland. We aim to fill this gap.
We explored what aspects of WGS patients and families 
with rare conditions in Scotland value. We conducted face-
to-face interviews with a subset of SGP study probands and 
their families. Where possible, the methods used for this 
qualitative interview study were developed in accordance 
with the Consolidated Criteria for Reporting Qualitative 
Studies (COREQ) guidelines (Tong et al. 2007). The study 
was approved by Scotland A Research Ethics Committee 
(NHS Tayside) and NHS R&D (REC Ref. 16/NS/0137).
Sample recruitment
We used a convenience sample of ten SGP probands and 
parents who were approached for consent and recruited fol-
lowing their appointment at the NHS Grampian regional 
genetics clinic. Eligible interview participants were English-
speaking adults (over the age of 18) with a rare condition 
with residual unmet diagnostic need, or parents of a child 
with an undiagnosed rare condition. None of the participants 
had received WGS results prior to the interview. Following 
providing consent, individuals were invited to attend a single 
face-to-face interview. Participants were informed that the 
length of the interview would be between 30 and 45 min.
Study process
Interviews were conducted in July 2018 at the Health Eco-
nomics Research Unit (HERU), University of Aberdeen. 
A research fellow (BM) facilitated all interviews. Train-
ing in qualitative interview methods was provided by an 
experienced qualitative researcher at HERU. There was no 
relationship between the interviewer and the study partici-
pants prior to study commencement. Each interview was 
audio-recorded and transcribed by a professional third-party 
transcription provider. The interviews were conducted as 
‘think aloud’ sessions, where participants were encouraged 
to verbalise their thought process when answering each 
question. This helps to ensure that respondents understand 
the questions whilst also providing valuable insight into the 
thought process behind each of their answers (Ryan et al. 
2008; Rigby et al. 2020).
Interview schedule
The interviewer followed a semi-structured script during 
the think aloud interviews. The interview schedule is avail-
able for reference in Online Resource 3. The schedule was 
informed by a systematic review of preference-based valua-
tion in genomics and genetic testing (Weymann et al. 2019). 
To get respondents to think about the potential benefits of 
WGS, they were initially asked to rate five attributes of WGS 
in terms of their importance using a five-point scale whilst 
verbalising their thought process behind each rating. The 
themes were as follows: chance of receiving a diagnosis; 
waiting times for results; information for family members; 
information about other conditions; and contributions to 
research. These attributes were identified using expert clini-
cal opinion and systematic review of the existing literature 
on preference-based valuation of WGS (Regier et al. 2009; 
Pélissier et al. 2016; Lewis et al. 2018; Peyron et al. 2018). 
Participants were also asked to comment on other factors 
important to them in the delivery of WGS. Throughout 
the interview, probing statements and prompts were used 
to encourage participants to engage with the ‘think aloud’ 
aspect of the interviews and to provide information about 
what is important to them in the delivery of WGS, and 
why. In addition to reminders to read and think aloud, the 
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interviewer asked probing questions regarding the value of 
a diagnosis with and without available treatment.
To inform the levels of a cost attribute in our future DCE, 
we included a willingness to pay (WTP) question (Donald-
son 1990). Individuals were asked directly how much they 
would be willing to pay for WGS where there is a chance 
(not a guarantee) that they may receive a genetic diagnosis; 
they can expect to wait between 6 months and 2 years for 
their results; health-related information would be provided 
to other family members if a genetic cause affects them; 
they can choose whether or not they receive information 
on secondary findings; and the research will benefit future 
healthcare for others with similar rare genetic conditions. 
Following participants’ initial response to the WTP ques-
tion, the interviewer asked further probing questions about 
whether (and by how much) their WTP value would change 
if a diagnosis was guaranteed, and if treatment was available 
following a diagnosis.
Analysis of qualitative data
An iterative thematic analysis approach was adopted to iden-
tify, extract and code relevant themes (Braun and Clarke 
2014). One analyst (BM) identified relevant themes and 
extracted supporting quotations. A second analyst (MA) 
independently reviewed the interview transcripts and 
extracted supporting quotations. The wider research team 
discussed and refined the emergent themes and finalised the 
aspects of WGS which participants valued.
Results
Costing the standard genetic testing pathway
We identified a complex and varied range of testing histo-
ries. This included a range of initial imaging, biopsy, meta-
bolic and biochemical investigations followed by first-line 
genetic testing (i.e. microarray, FISH and karyotype). Fol-
lowing these tests, the standard genetic testing pathway his-
tories revealed a diagnostic sub-odyssey comprising multiple 
single gene tests, gene panels and in some cases, epigenetic 
testing. The total numbers of tests per patient in the diag-
nostic sub-odyssey ranged from one to sixteen (mean = 2.32; 
standard deviation (SD) = 2.08; median = 2; inter quartile 
range (IQR) = 2).
Cost estimates for the 259 probands are shown in Table 1. 
There was significant variability in the overall cost of the 
pre-WGS genetic testing pathway, with an estimated mean 
total testing cost of £1013 per singleton patient, and a 
median cost of £850. The distribution was right-skewed 
with a wide range, from £90 to £6784. Two outpatient 
appointments and one genetics clinic appointment gave 
an additional cost of £828. This results in a mean standard 
genetic testing pathway cost of £1841 per patient.
The 259 patients fell into 19 rare disease categories. 
Results by rare disease category are shown in Fig. 3 for cat-
egories with three or more patients. The largest categories 
were intellectual disability (37%) and neurodevelopmental 
and neurological disorders without intellectual disability 
(21%). Five categories included 1–2 patients: gastroentero-
logical disorders (n = 1); dermatological disorders (n = 1) 
and growth disorders (n = 1); genomic medicine service 
indications (n = 2) and hearing and ear disorders (n = 2).
Considerable cost variation was observed both between 
and within rare disease categories. For categories with more 
than two cases, the mean cost ranged from £1362 to £2701. 
Outliers were observed for two categories (neurological/neu-
rodevelopmental and ultra-rare disorders), where the stand-
ard genetic testing pathway was estimated to cost around 
£7500; around three times greater than the mean cost for 
these patients. This was largely due to high numbers of sin-
gle gene tests.
Costing trio‑based whole genome sequencing
Detailed costs for each key component, along with relevant 
underlying assumptions, are shown in Table 2. The total cost 
of WGS was £6625 per trio. All costs are reported in 2018 
British Pounds.
The estimated cost for screening for WGS eligibility 
was £132 per trio. Allowing for 40% of children not requir-
ing a new DNA sample, estimated costs for consent and 
sample collection are £96 per trio. Phenotype data for all 
affected members was entered into a database, estimated to 
take between 15 min and 1 h, at an average cost of £58 per 
trio. The resource use by the regional genetics laboratory 
for DNA extraction was estimated at £187 per trio with an 
additional £30 per trio for sample send-away.
The largest component of the overall cost of providing 
WGS was the sequencing itself. Sequencing costs were 
based on the amount charged per sample (and pro rata per 
trio) by Edinburgh Genomics for the SGP WGS study. At 
Table 1  Estimated costs of the standard genetic testing sub-odyssey
a Assuming two general outpatient and one clinical genetics outpatient 
attendances. If there were the same number of general outpatient but 
twice as many clinical genetics visits, then the cost of hospital attend-
ances would be £1064.78
N = 259
Mean (SD) £1013.03 (£942.01)
Median £850.00
Minimum; Maximum £90.00; £6784.39
Hospital  Attendancesa £828
Total cost (mean + hospital attendances) £1841
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the time of the study in 2018, this was £850 per sample, 
excluding VAT (£3,060 per trio, inclusive of VAT). This 
cost represented 46% of the overall cost of providing WGS.
The second-largest component of the estimated WGS cost 
was data analysis. The cost of an encrypted FASTQ data file 
being created by the sequencing centre and sent to Genomics 
England (GeL) for data analysis, including the generation 
of Variant Call and BAM files plus bioinformatic analysis, 
was estimated at £1,684 per trio, including VAT. The data 
analysis costs accounted for 25% of the overall WGS cost.
De-identified information from the GeL data analysis 
and report was stored securely at the GeL database at a cost 
of £540 per trio. Following data analysis at GeL, identi-
fied variants were interpreted at one of the four regional 
genetics laboratories, at a cost of £297 per trio. An estimate 
for the multi-disciplinary team (MDT) meeting was based 
on recent MDT experience in the NHS Grampian genetics 
clinic, and was £68 per trio. Finally, a follow-up appointment 
for discussion of test results, assuming all cases get follow-
up, was £158 per trio.
Identifying the Benefits of Whole Genome 
Sequencing
Sample information, genetic and demographic 
characteristics
Of the ten participants invited, nine consented to take 
part in the think aloud interviews. The sample consisted 
of six parents of children with rare conditions and three 
affected adults. The average length of time participants 
had been seeking a genetic diagnosis was 3.2 years for 
adult probands, and 3.6 years for children. However, this 
was highly variable, with a range of 6 months to 8 years 
and 1 to 6.5 years for adults and children, respectively. 
The age of onset of symptoms of the rare condition for 
Fig. 3  Costs of standard genetic testing by phenotype/rare disease 
category. Figure 3 illustrates the costs of the standard genetic testing 
pathway by phenotype category. The median cost of standard care 
for each phenotype category (for groups with n > 2) is shown by the 
horizontal line within each box. The outer whisker lines indicate the 
minimum and maximum costs for each phenotype category, exclud-
ing outliers. Outliers are shown as ‘dots’ and represent the obser-
vations with unusually high or low test costs in comparison to the 
median for that phenotype. Outliers were generally patients with large 
numbers of single gene tests and an expensive gene panel test. Note: 
The median cost of standard care for each category is shown by the 
horizontal line within each box. The outer whisker lines indicate the 
minimum and maximum costs for each category, excluding outliers. 
Outliers are shown as ‘dots’ and represent the observations with unu-
sually high or low test costs in comparison to the median for that cat-
egory. Outliers were patients with large numbers of single gene tests 
and an expensive gene panel test. 1Phenotype/rare disease categories 
defined by the Genomics England Classification system (Genomics 
England 2018)
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adults in the sample ranged from 10 to 39 years, whilst 
the age of onset of children ranged from 5 months to 
2 years. A wide range of testing was reported prior to 
WGS with two adults and six parents reporting genetic 
testing prior to their WGS referral: two adults and two 
parents reported operative procedures; one adult and five 
parents reported other non-genetic tests (e.g. MRI, CT, 
X-Ray) prior to enrolment in the SGP study.
Rating questions
All explored dimensions of benefit of WGS (chance of 
diagnosis, waiting time, information for family mem-
bers, information about other conditions, contributions 
to research) were important to parents and affected adults. 
Four of the nine participants rated every attribute at the 
highest level of importance (5 = extremely important). 
When asked if any other factors were important to them 
about WGS, respondents consistently cited ‘having an 
answer’ and ‘closure’ as aspects of value. These factors 
were linked to the chance of receiving a diagnosis via 
WGS and reducing the uncertainty associated with the 
diagnostic odyssey.
Qualitative thematic analysis
Our thematic analysis revealed further insight into the 
value of WGS with respect to three aspects of value: a 
diagnosis; information provided; and contributions to 
research.
1. The value of a diagnosis
As expected, parents of children with rare conditions 
and affected adults consistently stated that they would 
value obtaining a diagnosis from WGS. The value of a 
diagnosis was generally centred around reducing the 
uncertainty associated with the diagnostic odyssey. Par-
ticipants cited ‘peace of mind’, and ‘closure’ as reasons 
why they would value a diagnosis:
‘I think for your peace of mind it’s invaluable.’ – 
Parent 1
‘It would benefit [child] if he could get medication… 
they could maybe treat him… Benefit for mum and 
dad would be… just put closure? How could you 
explain that? Knowing a reason why gives us clo-
sure.’ – Parent 3
Table 2  Whole genome sequencing costs
*Includes the cost of sending an encrypted FASTQ data file to Genomics England (GeL) for data analysis, including encrypted file transfer, gen-




% Total WGS cost
WGS SGP Protocol (Trio) £662,520
Timing of WGS After standard clinical, non-genetic, molecular genetic and cytogenetic 
testing
Time horizon 1 year
Screening and recruitment Screening and recruitment undertaken by regional genetics centres £132.63 2.00%
Consent and obtaining blood 
sample for DNA extraction
40% of probands did not require new sample to be taken. 75% probands 
requiring new sample needed a separate hospital visit for taking this 
sample
£96.42 1.46%
Phenotyping Phenotype data entered into OpenClinica according to SGP protocol £58.17 0.88%
Sample reception Sample reception and book in at regional genetics laboratory £8.80 0.13%
DNA extraction Batch Size of 24 £186.88 2.82%
Sample send-away Batch size 3 (Trio) £30.00 0.45%
Sequencing of DNA Cost charged to study by Edinburgh Genomics per Trio £3,060.00 46.19%
Data analysis As per 100,000 Genomes Protocol at GeL; cost charged to study by GeL £1,684* 25.42%
Data storage As per 100,000 Genomes Protocol by GeL; cost charged to study by GeL £540.00 8.15%
Variant interpretation Average of 4 variants per case (Trio-based analysis, exonic variants). No 
additional testing required to aid variant classification
£305.24 4.61%
Variant Validation Potentially pathogenic variants confirmed by Sanger sequencing £296.87 4.48%
MDT meeting to discuss findings 50% require MDT meeting. Time per case 5–20 min £67.99 1.03%
Patient feedback No data available on % trios who get feedback via genetics clinic visit. 
Costs assume all cases get feedback at clinic appointment
£158.20 2.39%
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Notably, participants valued obtaining a diagnosis via 
WGS, even if there was no treatment available. When a 
probing question was asked about whether the participant 
would still value a diagnosis without any available treat-
ment, several participants expressed that having a name 
for the condition would be valuable in itself:
‘But that would put your mind at rest a wee bit, do 
you know what I mean?’ – Parent 1
‘I just feel as a parent, if I knew what was wrong, I 
feel that I could have closure… So that would be my 
benefit as a parent.’ – Parent 3
‘I’d just want to know what’s wrong, whether you 
can solve it… you just don’t know what’s wrong with 
him, so it’s just the fact that you could put a label on 
it. It’s just that peace of mind that, okay, that’s what 
he’s got. It’s the unknown.’ – Parent 4
‘I think it’s the satisfaction of having an answer… 
Yeah, it’s satisfying curiosity. A bit of knowledge 
about the subject…I like to have an answer about 
things.’ – Parent 5
2. The value of the information provided by WGS
Further probing provided insight into two informational 
benefits of WGS. Firstly, participants valued information 
for family members regarding their chance of develop-
ing or passing on the condition. Secondly, patients and 
families valued receiving information regarding other 
health conditions unrelated to the rare condition (second-
ary findings).
‘When else would I get the opportunity to get that 
information? And when I have that information then 
I can maybe make a more informed decision myself 
about telling who in the family and so on, so I’m 
going to put extremely important.’ – Adult 1
3. Contributions to research and benefits beyond the indi-
vidual
Both parents of affected children and affected adults 
recognised that, whilst there is a chance of diagnosis from 
WGS, there may not necessarily be available treatments or 
improvements in quality of life following the identification 
of a pathogenic genetic variant. Furthermore, participants 
were aware that a diagnosis via WGS is not a guarantee. 
Nevertheless, the possibility of benefiting future patients 
and contributing to the genomic evidence base was cited 
as valuable:
‘Because that’s why I’m here today. I hope to help 
others as well.’ – Adult 1
‘Extremely important because other people need help 
too.’ – Adult 3
‘Well, it seems like… this is not really for his ben-
efit particularly. There’s a chance it could benefit him 
in some way, but realistically, it’s more to kind of go 
towards research and kind of… preventative future sort 
of things.’ – Parent 5
Willingness to pay for whole genome sequencing
Seven of the nine participants provided a WTP value for 
WGS, ranging from £200 to £5000 (Table 3). The two par-
ticipants who did not provide a value indicated that they 
would pay for the test, but could not quantify how much they 
would be willing to pay.
WTP probing questions provided further insight into what 
users of the service valued. Responses depended on the fea-
tures of WGS described in the survey, particularly the chance 
of receiving a diagnosis and the possibility of improvement 
in quality of life. One respondent stated that they would be 
willing to pay much more for WGS if a genetic diagnosis 
was guaranteed. Similarly, one respondent stated that they 
would be willing to pay much more if there was a treatment 
available following a genetic diagnosis:
‘The price of something less for [child] to worry about 
is invaluable.’ – Parent 1
‘If I was to get a guaranteed result, I would pay what-
ever I needed to pay to get a result if it would help 
professionals make life better for [child], we’d pay 
anything.’ – Parent 3
‘I thought if there was a chance that there was going 
to be some sort of treatment from it, to help his condi-
tion, I think it would be, obviously, much more likely 
to spend money on…’ – Parent 5
Table 3  Willingness to pay values
A affected adult; P parent of affected child.




P1 Would pay but can’t quantify
P2 £500
P3 £5000
P4 Willing to pay for WGS 
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‘If I knew we were definitely going to get an abso-
lute result and there was something that might help 
us or more importantly help my daughter, what price 
would you put on that? It’s a really difficult question 
to answer.’ – Parent 6
Discussion
In this exploratory study, we estimated the cost of standard 
(singleton) genetic testing and trio-based WGS according 
to the SGP study protocol. We also conducted qualitative 
research with SGP participants to inform the development of 
a DCE. Below we summarise our findings, as well as areas 
identified for further investigation.
Assessing the costs of standard genetic testing
Standard genetic testing histories revealed a diagnostic ‘sub-
odyssey’ comprising a complex range of single gene, gene 
panel and some epigenetic tests, with considerable hetero-
geneity between phenotypes. The mean cost of the standard 
genetic testing pathway, including hospital attendances, was 
£1841, with a range from £90 to £6784. We found significant 
variability in both the length and scope of the diagnostic 
odyssey. Outliers were generally cases with a large number 
of single gene tests or, in one case, a particularly costly gene 
panel test. Given that the consortium structure of genetics 
in Scotland is designed to minimise differences in the care 
patients receive, regional differences in how healthcare is 
accessed or delivered are unlikely to explain variations. We 
did not remove outliers since these cases are expected to 
occur in a rare disease population.
Our costing exercise has a number of shortcomings. Our 
costs were based on the prior testing histories of a sample of 
‘difficult-to-diagnose’ patients, according to the SGP study 
eligibility criteria. These criteria limit the generalisability 
of our estimated costs beyond this patient group. Further-
more, our estimated costs are for singleton probands, and 
do not account for the cost of confirmatory and/or wider 
family testing. In cases where a genetic variant is identified 
via standard testing, confirmatory testing and wider family 
testing would typically take place. However, the SGP study 
eligibility criteria required that patients test negative on all 
prior genetic tests. Our clinical advice therefore suggested 
that the vast majority of standard genetic testing would be 
conducted on a singleton basis in this sample. As a result, 
any additional costs which might be incurred by other family 
members would be minimal in this context. It is likely that, 
in other contexts, where eligibility criteria do not require 
negative results on all standard genetic testing, confirmatory 
and wider family testing would result in higher costs.
Given the sample size, cost estimates for some phenotype 
subgroups lack precision. Our assumed number of hospital 
attendances may be an underestimate (given that patients 
often receive a series of tests over many years). Data on prior 
testing histories was based on eligibility screening forms, 
which only required sufficient information on prior genetic 
testing to assess eligibility for the SGP study. Different cli-
nicians may supply varying levels of detail. As such, our 
costs may be an underestimate. Genetic testing histories in 
approximately one-third of screening forms could not be 
fully identified due to missing information, or where forms 
were handwritten and the name(s) of some genetic test(s) 
were unclear. We excluded these cases as full cost infor-
mation could not be estimated for all tests. Furthermore, 
various sources were used to identify unit costs for stand-
ard genetic testing. Where possible, unit costs provided by 
Scottish genetics laboratories were used. However, in cases 
where Scottish unit costs were unavailable, UK unit costs 
were used. Where no UK unit cost data was available, costs 
were estimated based on the number of amplicons in the 
gene or gene panel. Combining these disparate sources of 
unit cost data may limit the consistency of our cost esti-
mates. Additionally, we did not conduct a formal statistical 
analysis to quantify uncertainty in point estimates. Finally, 
due to data limitations, we could not annualise costs, and 
we thus do not know if higher standard care costs were due 
to longer diagnostic odysseys, more intensive care or both.
Future work will address the limitations of our costing 
estimates by extracting data from patients’ medical notes. 
More specifically, we will collect detailed data on SGP study 
probands’ prior genetic testing histories and relevant hospital 
attendances (including the year/month). Data will also be 
collected on patients’ genomic test report (positive, negative, 
variants of unknown significance), any parallel testing and 
additional testing for clarification. Details of any follow-up 
action taken resulting from the outcome of the genomic test 
will also be collected. This will allow us to more precisely 
characterise the genetic testing component of the diagnostic 
odyssey on an individual and annualised level. We will char-
acterise the uncertainty around point estimates for the costs 
of the standard care pathway by conducting probabilistic 
sensitivity analysis.
Assessing the costs of whole genomic sequencing
Trio-based WGS was estimated to cost £6625 per trio, reflect-
ing WGS as per the SGP study protocol and early experience 
of WGS. Whilst the costing in this paper was limited to the 
practice in one of four Scottish genetics centres, communica-
tion with the other three Scottish genetics centres indicates that 
our estimates are generalisable across Scotland. However, we 
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will extend our WGS micro-costing from one genetics centre 
in Scotland to all four regional genetics centres.
The costs of WGS estimated in this study should be inter-
preted in the context of the assumptions made, as well as in the 
context of the SGP study in Scotland. Varying the assumptions 
made regarding the WGS process will inevitably impact the 
estimated cost. At the time of the study, WGS interpretation 
was still bedding within NHS Scotland laboratories and clinics 
and the process for reviewing results was not fully developed. 
The costs associated with this element are expected to reduce 
as the process evolves. For example, MDT meeting formats 
tended still to be ‘atypical’ and on a learning curve as they 
continued to improve efficiency in terms of numbers/grades of 
staff required. The key driver of cost was sample sequencing, 
data analysis and data storage. Approximately 46% (£3060) 
of the total WGS cost was accrued from the sequencing itself, 
with a further 25% (£1684) at the data analysis stage. A reduc-
tion in these costs will significantly impact the total cost of 
providing WGS. Furthermore, bioinformatics and storage costs 
were high during the 100,000 Genomes Project, due to the 
upfront costs of developing the infrastructure from scratch. 
WGS is likely to be less expensive if delivered at scale (rather 
than in a research context). Similarly, advances in analytical 
methods that enable accurate variant filtering for singletons 
would reduce the cost of WGS testing, by reducing the need 
to sequence the DNA of family members (Boycott et al. 2013). 
Classification of variants is likely to become more automated 
and less labour intensive in the future, although any impact on 
the overall cost of WGS is uncertain.
Data were not available to consider the long-term impli-
cations on the diagnostic odyssey beyond the elements of the 
genetic testing pathway potentially replaced by WGS. The 
long-term and downstream cost implications of WGS are 
important to consider going forward, e.g. costs of confirma-
tory testing, data reanalysis, changes to patient management, 
incidental findings and reproductive decisions (Schofield 
et al. 2019; Doble et al 2020). However, this is beyond the 
scope of our study.
In this study, the comparator to standard genetic test-
ing was restricted to WGS. Other novel developments in 
genomic medicine, such as whole exome sequencing (WES), 
which was delivered to patients in the Deciphering Develop-
mental Disorders (DDD) study in Scotland (Firth and Wright 
2011), may also offer a cost-effective alternative to stand-
ard care. Given that trio-based WES is being offered on an 
interim basis in a diagnostic context within NHS Scotland, 
we will also micro-cost WES in the same detail as WGS.
Identifying the benefits of whole genome 
sequencing
Our think aloud interviews provide qualitative evidence that 
patients and families with undiagnosed rare conditions value a 
broad range of health and non-health outcomes associated with 
WGS. This provides support for the need to go beyond clinical 
measures of benefit such as diagnostic yield when assessing 
the value of genome-scale sequencing from a user perspective. 
For example, several participants cited ‘peace of mind’ and 
‘closure’ as valuable aspects of WGS. These aspects of value 
were interpreted as being related to reducing the stress and 
uncertainty of the diagnostic odyssey. Additionally, patients 
and families recognise that, even if they do not receive a diag-
nosis immediately, their genome sequence data may benefit 
others in the future. Our WTP results provide further evidence 
of the value of WGS beyond diagnostic yield alone.
Our rating exercise found that all aspects of WGS (chance 
of diagnosis, waiting time for results, information provided 
by the test and contributions to research) were important to 
patients and families. It is possible that framing effects influ-
enced this finding, with all aspects presented positively, e.g. 
chance of receiving a diagnosis and the possibility of contrib-
uting to research and helping others with undiagnosed rare 
conditions. However, this finding is more likely a consequence 
of the shortcoming of rating questions, where individuals do 
not have to make trade-offs between aspects of care (Cleland 
et al. 2018). A planned DCE will force individuals to make 
trade-offs between different aspects of care.
The main limitation of our think aloud study is the sample 
size, with nine respondents (six parents of affected children 
and three affected adults). Given that our findings are consist-
ent with other qualitative studies, in similar contexts, we are 
confident that we have captured what is important to users of 
genomic testing in Scotland (Pollard et al. 2021; Mackley et al. 
2018; Lewis et al. 2020; Goranitis et al. 2020; McCarthy et al. 
2020). Nonetheless, future developmental work will explore 
this further. Our Project Advisory Group includes the Scottish 
Policy and Engagement Manager for Genetic Alliance UK; 
we will use this group to further explore what is important to 
users. Following this, we will develop a DCE which will be 
sent to all families affected by rare disorders who participated 
in (i) the SGP study collaborating with the 100,000 Genomes 
Project (excluding those who have participated in our develop-
mental work) and (ii) the Deciphering Developmental Disor-
ders (DDD) study. Our DCE results will be incorporated into 
a user-perspective cost–benefit analysis of WGS and WES vs 
standard care. This will allow us to value the broader benefits 
of genome-wide sequencing which are important to patients 
and families with rare conditions, such as the provision of 
information.
Conclusions
Trio-based WGS is a costly investigation in comparison to 
the current standard genetic testing pathway in Scotland. 
However, an increase in diagnostic yield and additional value 
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may justify the additional cost. Greater clarity is needed on 
both the costs and benefits of genome-wide sequencing to 
inform Scottish Government policy and its funding in clini-
cal practice. This paper adds to the economic evidence base 
on assessing the costs and benefits of WGS for the diagnosis 
of rare conditions. Our exploratory costing study will guide 
a detailed costing of the diagnostic odyssey, with access 
to a larger sample and patient case notes and the update 
of our WGS costing to reflect changes in service delivery 
and costs since 2018. These updated costs will feed into a 
budget impact analysis, a cost-effectiveness analysis (cost 
per diagnostic yield) and a user perspective cost–benefit 
analysis (taking account of all factors important to patients 
and their families). Along with further developmental work, 
our qualitative think aloud findings will guide the develop-
ment of a discrete choice experiment. This DCE will be sent 
to a large sample of patients and families with rare condi-
tions in Scotland. Stated preference data will then be used 
in our user-perspective cost–benefit analysis, to account for 
the wide range of health and non-health outcomes which 
are important to patients and families. Taken together, our 
research will inform the long-term strategic development of 
NHS Scotland clinical genetics testing services and will be 
of benefit to others seeking to undertake similar evaluations 
in different contexts.
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